#Switzerland #ADC Therapeutics #Lausanne #ZYNLONTA® #Marginal Zone Lymphoma

ADC Therapeutics Unveils Updated Trial Data for ZYNLONTA® in Marginal Zone Lymphoma

ADC Therapeutics SA, a notable player in the antibody drug conjugate (ADC) sector, has released updated findings from a Phase 2 investigator-initiated trial (IIT) showcasing the efficacy of ZYNLONTA® in treating relapsed/refractory marginal zone lymphoma (r/r MZL). This data is poised to be presented at the 18th International Conference on Malignant Lymphoma (ICML) taking place in Lugano, Switzerland.

The trial data demonstrates a robust overall response rate (ORR) of 85%, with 69% of the patients achieving complete response (CR). Impressively, among those who obtained CR, 17 patients retained their response, with the longest duration noted at 27 months from the commencement of treatment. These findings further reinforce ZYNLONTA's potential as a single-agent therapy for patients suffering from this challenging form of lymphoma.

Dr. Izidore S. Lossos, the principal investigator and Chief of the Division of Hematology Lymphoma Section at Sylvester Comprehensive Cancer Center, commented on these compelling results. He emphasized that the treatment was well-tolerated among participants and the safety profile aligns with previously known data. This single-arm, open-label study included 27 adult patients who had previously undergone systemic therapy.

Further details include an ORR of 84.6% (22 out of 26 evaluable patients) and a noteworthy CR rate of 69.2% (18 out of 26). For patients identified as high-risk POD24, the CR rate reached 61.5%. Progression-free survival (PFS) at 12 months was reported at an impressive 92.9%. The safety reporting indicated adverse events were mostly mild, predominantly grade 1 or 2, with a few grade 3 and 4 occurring in a minority of patients. Notably, one patient discontinued treatment following cycle 4 due to a temporary cholesterol-induced liver condition but fully recovered later.

This ongoing research, conducted not only at Sylvester Comprehensive Cancer Center but also at City of Hope, Emory Winship Cancer Institute, and Vanderbilt-Ingram Cancer Center, aims to enroll 50 patients diagnosed with r/r MZL. Dr. Mohamed Zaki, Chief Medical Officer of ADC Therapeutics, expressed optimism regarding the potential of ZYNLONTA, especially if future data remains promising, hinting at a regulatory pathway ahead.

In addition to the r/r MZL trial updates, an oral presentation featuring the results from the LOTIS-7 Phase 1b trial will also be shared at the same conference, revealing ZYNLONTA's effects when combined with the bispecific antibody glofitamab in patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

About ZYNLONTA®
ZYNLONTA® is a targeted therapy designed to deliver a potent payload directly to cancer cells expressing the CD19 antigen. Upon binding, ZYNLONTA enters the cell where it releases a pyrrolobenzodiazepine payload, resulting in cell death. This innovative approach addresses challenging hematologic malignancies and has received accelerated approval from the FDA and conditional approval in the EU for r/r large B-cell lymphoma.

ADC Therapeutics, headquartered in Lausanne, Switzerland, remains dedicated to advancing ADC technologies aimed at transforming cancer treatment paradigms globally. For more details about their ongoing trials and research, visit ADC Therapeutics.